Summary of randomized trials of hydroxyurea and interferon in ET and PV
| Trial . | Patients . | Arms . | N . | CHR at 24 months . | Discontinuation rate because of AEs . | Additional comments . |
|---|---|---|---|---|---|---|
| MPN-RC 11231 | High-risk ET (n = 81) or PV (n = 87) | HU | 80 | 20% | 11% | PEG-IFN led to greater reduction in JAK2V617F; HU had more histopathologic responses |
| PEG-IFN | 82 | 29% | 15% | |||
| DALIAH33,44 | Newly diagnosed ET, PV, pre-PMF, or PMF | HU | 38 | 21% | 13% | Median JAK2V617F reduction was greater at 36 months in PEG-IFN arm compared to HU |
| PEG-IFNa | 164 | 26% | 34% | |||
| PROUD-PV/ CONTINUATION-PV45 | High-risk PV untreated or <3 years of HU | HU | 76 | 49% | 4% | Molecular responses were higher in the ROPEG-IFN arm compared to standard therapy at 24 and 36 months |
| ROPEG-IFN | 95 | 71% | 8% |
| Trial . | Patients . | Arms . | N . | CHR at 24 months . | Discontinuation rate because of AEs . | Additional comments . |
|---|---|---|---|---|---|---|
| MPN-RC 11231 | High-risk ET (n = 81) or PV (n = 87) | HU | 80 | 20% | 11% | PEG-IFN led to greater reduction in JAK2V617F; HU had more histopathologic responses |
| PEG-IFN | 82 | 29% | 15% | |||
| DALIAH33,44 | Newly diagnosed ET, PV, pre-PMF, or PMF | HU | 38 | 21% | 13% | Median JAK2V617F reduction was greater at 36 months in PEG-IFN arm compared to HU |
| PEG-IFNa | 164 | 26% | 34% | |||
| PROUD-PV/ CONTINUATION-PV45 | High-risk PV untreated or <3 years of HU | HU | 76 | 49% | 4% | Molecular responses were higher in the ROPEG-IFN arm compared to standard therapy at 24 and 36 months |
| ROPEG-IFN | 95 | 71% | 8% |
PEG-IFN included both interferon-α-2a and interferon-α-2b.
PMF, primary myelofibrosis; PR, partial response.